Quris, a Boston and Tel Aviv, Israel-based artificial intelligence (AI) innovator disrupting the pharmaceutical arena, announced that it secured an additional $9 million in seed funding, bringing its total seed round funding to $37 million.
The round was by SoftBank Vision Fund 2, alongside existing private and institutional investors such as GlenRock Capital, iAngels, Welltech Ventures, and Richter Group.
The additional capital will help Quris advance its Bio-AI platform, grow its team, strengthen industry collaborations, and speed up its novel drug research.
“SoftBank’s ecosystem comprises an impressive cluster of companies leading the field of artificial intelligence for pharma. As an investment partner, it gives them a unique perspective on this young and promising field that has already begun to produce significant unicorns,” added Dr. Isaac Bentwich, founder and CEO of Quris.
Quris is a Bio-AI clinical prediction platform that simulates clinical trials by leveraging a patented patient-on-chip system through the use of stem-cell-derived tissue and AI to simulate a real human body’s reaction to drugs without relying on time-intense, inaccurate animal testing.
Company: Quris Technologies LTD
Round: Seed Round
Funding Month: December 2022
Lead Investors: SoftBank Vision Fund 2
Additional Investors: GlenRock Capital, iAngels, Welltech Ventures, and Richter Group
Company Website: https://www.quris.ai/
Software Category: AI Clinical Prediction Platform
About the Company: Quris is the first Bio-AI clinical prediction platform that ensures the safety and efficacy of new drugs. Revolutionizing the drug development process, the company is pioneering clinical trials on chips – testing thousands of novel drug candidates on hundreds of miniaturized “patients-on-a-chip”. Its fully automated, self-training AI platform accurately predicts clinical safety and efficacy for novel drugs faster and more cost-effectively than ever before – all while minimizing animal testing. Dual-headquartered in Boston and Israel and backed by strategic biotech and big data investors, Quris is led by a proven team of AI and medical research powerhouses who are already preparing its lead discovery for clinical trials.